51
|
Collins D, Alexander C, Darimont CT. Staqeya: the lone wolf at the edge of its ecological niche. Ecology 2018; 100:e02513. [PMID: 30198558 DOI: 10.1002/ecy.2513] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2018] [Revised: 08/27/2018] [Accepted: 09/05/2018] [Indexed: 11/08/2022]
|
52
|
Bobrovitz N, Heneghan C, Onakpoya I, Fletcher B, Collins D, Tompson A, Lee J, Nunan D, Fisher R, Scott B, O’Sullivan J, Van Hecke O, Nicholson BD, Stevens S, Roberts N, Mahtani KR. Medications that reduce emergency hospital admissions: an overview of systematic reviews and prioritisation of treatments. BMC Med 2018; 16:115. [PMID: 30045724 PMCID: PMC6060538 DOI: 10.1186/s12916-018-1104-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 06/19/2018] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Rates of emergency hospitalisations are increasing in many countries, leading to disruption in the quality of care and increases in cost. Therefore, identifying strategies to reduce emergency admission rates is a key priority. There have been large-scale evidence reviews to address this issue; however, there have been no reviews of medication therapies, which have the potential to reduce the use of emergency health-care services. The objectives of this study were to review systematically the evidence to identify medications that affect emergency hospital admissions and prioritise therapies for quality measurement and improvement. METHODS This was a systematic review of systematic reviews. We searched MEDLINE, PubMed, the Cochrane Database of Systematic Reviews & Database of Abstracts of Reviews of Effects, Google Scholar and the websites of ten major funding agencies and health charities, using broad search criteria. We included systematic reviews of randomised controlled trials that examined the effect of any medication on emergency hospital admissions among adults. We assessed the quality of reviews using AMSTAR. To prioritise therapies, we assessed the quality of trial evidence underpinning meta-analysed effect estimates and cross-referenced the evidence with clinical guidelines. RESULTS We identified 140 systematic reviews, which included 1968 unique randomised controlled trials and 925,364 patients. Reviews contained 100 medications tested in 47 populations. We identified high-to moderate-quality evidence for 28 medications that reduced admissions. Of these medications, 11 were supported by clinical guidelines in the United States, the United Kingdom and Europe. These 11 therapies were for patients with heart failure (angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, aldosterone receptor antagonists and digoxin), stable coronary artery disease (intensive statin therapy), asthma exacerbations (early inhaled corticosteroids in the emergency department and anticholinergics), chronic obstructive pulmonary disease (long-acting muscarinic antagonists and long-acting beta-2 adrenoceptor agonists) and schizophrenia (second-generation antipsychotics and depot/maintenance antipsychotics). CONCLUSIONS We identified 11 medications supported by strong evidence and clinical guidelines that could be considered in quality monitoring and improvement strategies to help reduce emergency hospital admission rates. The findings are relevant to health systems with a large burden of chronic disease and those managing increasing pressures on acute health-care services.
Collapse
|
53
|
Carrelli P, Degeyter K, Collins D, Keating L, Mandato K, Herr A, Englander M, Stark C, Siskin G. Abstract No. 427 Proximal splenic embolization: an important role for IR in the treatment of splenic trauma. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
54
|
Sundar R, Custodio A, Petruckevich A, Chénard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye SB, Tunariu N, Banerji U, de Bono J, Lopez J. Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clin Oncol (R Coll Radiol) 2018; 30:185-191. [PMID: 29224898 DOI: 10.1016/j.clon.2017.11.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 10/19/2017] [Accepted: 11/22/2017] [Indexed: 11/25/2022]
Abstract
AIMS Advanced biliary tract carcinomas (ABC) are malignancies with limited effective therapies for advanced disease. There is little published evidence of outcomes of ABC patients participating in phase I clinical trials. MATERIALS AND METHODS Patient characteristics, treatment details and outcomes of ABC patients treated at a dedicated phase I unit were captured and analysed from case and trial records. RESULTS In total, 123 ABC patients were included in the study, of which 48 patients participated in 41 different phase I trials; 75 (61%) did not participate due to rapid disease progression or patient choice. Molecular characterisation of tumours using a targeted panel was conducted in 15 (31%), yielding several potentially actionable mutations, including BRCA, PIK3CA, FGFR, AKT and PTEN loss. Of the 39 evaluable patients there was one exceptional responder. Eighteen (46%) other patients achieved stable disease as their best response, with a clinical benefit rate at 4 months of 10%. Treatment was generally well tolerated with grade 3 or 4 adverse events only observed in eight patients (17 %), of which six were drug related and led to trial discontinuation in one (3%), with no toxicity-related deaths. CONCLUSION Carefully selected ABC patients have been found to tolerate experimental phase I clinical trials without excess toxicity. The aggressive nature of this disease warrants consideration of early referral to a phase I unit. Future work will require comprehensive molecular profiling in an attempt to understand the biology underlying the exceptional responders and to match patients in real-time to targeted therapies.
Collapse
|
55
|
Denault LJ, Allen WG, Boyer EW, Collins D, Kramme D, Spradlin JE. A Simple Reducing Sugar Assay for Measuring β-Glucanase Activity in Malt, and Various Microbial Enzyme Preparations. JOURNAL OF THE AMERICAN SOCIETY OF BREWING CHEMISTS 2018. [DOI: 10.1094/asbcj-36-0018] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
56
|
Kilgannon AK, Holman B, Mawson AJ, Campbell M, Collins D, Hopkins D. Effect of Controlled Temperature-Time Variation during the Chilled Storage of Beef on Tenderness Characteristics. MEAT AND MUSCLE BIOLOGY 2018. [DOI: 10.22175/rmc2018.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
57
|
Clayton K, Collins D, Lengieza J, Lieberman J, Walker B. Intrinsic resistance of HIV-infected macrophages to CTL-mediated killing drives immune activation. J Virus Erad 2017. [DOI: 10.1016/s2055-6640(20)30631-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
58
|
Chenard-Poirier M, Hong D, Coleman R, de Bono J, Mau-Sorensen M, Collins D, Lisby S, Basse L, Lassen U. A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.049] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
59
|
Chenard-Poirier M, Hong D, Coleman R, de Bono J, Mau-Sorensen M, Collins D, Lisby S, Basse L, Lassen U. A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
60
|
Foltz K, Ritzi M, Barrett N, Evans N, Collins D, Sriranganathan N, Mahsoub H, Dalloul R, Sewell J, Persia M. Efficacy of Lactobacillus plantarum supplementation in broilers challenged with avian pathogenic Escherichia coli and Salmonella Typhimurium. J APPL POULTRY RES 2017. [DOI: 10.3382/japr/pfw074] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
61
|
Collins D, Hafidz F, Mustikawati D. The economic burden of tuberculosis in Indonesia. Int J Tuberc Lung Dis 2017; 21:1041-1048. [DOI: 10.5588/ijtld.16.0898] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
62
|
Gaynor N, Guibourdenche M, Browne B, O'Driscoll L, O'Brien N, O'Donovan N, Crown J, Collins D. Alterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (T-ADCC) in a lapatinib-resistant HER2+ breast cancer cell line model. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx361.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
63
|
Khan K, Cunningham D, Vlachogiannis G, Hedayat S, Rata M, Koh DM, Tunariu N, Jamin Y, Collins D, Chau I, Rao S, Watkins D, Starling N, Peckitt C, Fotiadis N, Saffery C, Hahne J, Fassan M, Braconi C, Valeri N. Clinical and pre-clinical biomarkers of Regorafenib (REG) efficacy in metastatic colorectal cancer (mCRC) in a phase II trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
64
|
Swilks E, Jenkins C, Poynting A, Collins D, Krebs GL. Prevalence and effect of Theileria orientalis
infection in homebred calves in the Gloucester region of New South Wales, Australia. Aust Vet J 2017; 95:211-216. [DOI: 10.1111/avj.12593] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Revised: 07/27/2016] [Accepted: 07/28/2016] [Indexed: 11/26/2022]
|
65
|
Huang A, Collins D, Glick S, Lee W. 411 Novel filaggrin gene polymorphisms in atopic dermatitis. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
66
|
Park P, Cole S, Collins D, Bercu Z, Newsome J. Understanding the patient preferences for femoral central venous catheterization among patients with sickle cell disease. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
67
|
Collins D, Henry L. Eyewitness recall and suggestibility in individuals with Down syndrome. JOURNAL OF INTELLECTUAL DISABILITY RESEARCH : JIDR 2016; 60:1227-1231. [PMID: 27381963 DOI: 10.1111/jir.12310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Revised: 04/29/2016] [Accepted: 05/27/2016] [Indexed: 06/06/2023]
Abstract
BACKGROUND Many criminal justice professionals perceive the eyewitness skills of individuals with intellectual disabilities to be weaker than those of typically developing (TD) individuals. Down syndrome (DS) is one of the most common genetic causes of intellectual disabilities, yet there is no research addressing eyewitness skills in this population. This study examined the eyewitness recall and suggestibility of young people with DS. METHOD Young people with DS and mental age-matched TD children viewed a video of a non-violent petty crime and were subsequently asked to freely recall the event before being asked general and specific questions incorporating both misleading and non-leading prompts. RESULTS Compared with mental age-matched TD individuals, young people with DS produced as much information, were just as accurate and were no more suggestible. CONCLUSIONS The eyewitness memory skills of young people with DS are comparable to those of mental age-matched TD children. The implications of these findings for the forensic context and eyewitness memory are discussed.
Collapse
|
68
|
Collins D, Lee J, Bobrovitz N, Koshiaris C, Ward A, Heneghan C. whoishRisk - an R package to calculate WHO/ISH cardiovascular risk scores for all epidemiological subregions of the world. F1000Res 2016; 5:2522. [PMID: 28357040 PMCID: PMC5345772 DOI: 10.12688/f1000research.9742.2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/06/2017] [Indexed: 02/03/2023] Open
Abstract
The World Health Organisation and International Society of Hypertension (WHO/ISH) cardiovascular disease (CVD) risk assessment charts have been implemented in many low- and middle-income countries as part of the WHO Package of Essential Non-Communicable Disease (PEN) Interventions for Primary Health Care in Low-Resource settings. Evaluation of the WHO/ISH cardiovascular risk charts and their use is a key priority and since they only existed in paper or PDF formats, we developed an R implementation of the charts for all epidemiological subregions of the world. The main strengths of this implementation are that it is built in a free, open-source, coding language with simple syntax, can be downloaded from github as a package (“whoishRisk”), and can be used with a standard computer.
Collapse
|
69
|
Kiamanesh O, Nazzari H, Shaipanich T, Collins D, Chakrabarti S, Wilson D, Ignaszewski A, Toma M. UTILIZATION OF PET IMAGING IN PATIENTS REFERRED TO SPECIALIZED CARDIAC SARCOIDOSIS CLINIC. Can J Cardiol 2016. [DOI: 10.1016/j.cjca.2016.07.235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
70
|
Sundar R, Custodio A, Lim J, Chenard-Poirier M, Collins D, Kaye S, Yap T, Banerji U, Lopez J, de Bono J. Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
71
|
Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Koenig W, Sacco R, Elkind M, Talmud P, Rimm E, Cannon CP, Packard C, Barrett-Connor E, Hofman A, Kardys I, Witteman JCM, Criqui M, Corsetti JP, Rainwater DL, Moss AJ, Robins S, Bloomfield H, Collins D, Packard C, Wassertheil-Smoller S, Ridker P, Ballantyne C, Cannon CP, Cushman M, Danesh J, Gu D, Hofman A, Nelson JJ, Thompson S, Zalewski A, Zariffa N, Di Angelantonio E, Kaptoge S, Thompson A, Thompson S, Walker M, Watson S, Wood A. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. ACTA ACUST UNITED AC 2016; 14:3-11. [PMID: 17301621 DOI: 10.1097/01.hjr.0000239464.18509.f1] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND A large number of observational epidemiological studies have reported generally positive associations between circulating mass and activity levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and the risk of cardiovascular diseases. Few studies have been large enough to provide reliable estimates in different circumstances, such as in different subgroups (e.g., by age group, sex, or smoking status) or at different Lp-PLA2 levels. Moreover, most published studies have related disease risk only to baseline values of Lp-PLA2 markers (which can lead to substantial underestimation of any risk relationships because of within-person variability over time) and have used different approaches to adjustment for possible confounding factors. OBJECTIVES By combination of data from individual participants from all relevant observational studies in a systematic 'meta-analysis', with correction for regression dilution (using available data on serial measurements of Lp-PLA2), the Lp-PLA2 Studies Collaboration will aim to characterize more precisely than has previously been possible the strength and shape of the age and sex-specific associations of plasma Lp-PLA2 with coronary heart disease (and, where data are sufficient, with other vascular diseases, such as ischaemic stroke). It will also help to determine to what extent such associations are independent of possible confounding factors and to explore potential sources of heterogeneity among studies, such as those related to assay methods and study design. It is anticipated that the present collaboration will serve as a framework to investigate related questions on Lp-PLA2 and cardiovascular outcomes. METHODS A central database is being established containing data on circulating Lp-PLA2 values, sex and other potential confounding factors, age at baseline Lp-PLA2 measurement, age at event or at last follow-up, major vascular morbidity and cause-specific mortality. Information about any repeat measurements of Lp-PLA2 and potential confounding factors has been sought to allow adjustment for possible confounding and correction for regression dilution. The analyses will involve age-specific regression models. Synthesis of the available observational studies of Lp-PLA2 will yield information on a total of about 15 000 cardiovascular disease endpoints.
Collapse
|
72
|
Collins D, Wright D, Cook H, Brightwell J, Denman R, Lee A. Diagnostic Benefit of 48 Hour Holter Monitors Compared to 24 Hour Holter Monitors. Heart Lung Circ 2016. [DOI: 10.1016/j.hlc.2016.06.299] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
73
|
Hoban J, Hopkins D, Kirby N, Collins D, Dunshea F, Kerr M, Bailes K, Cottrell J, Holman B, Brown W, Ponnampalam E. Application of small angle X-ray scattering synchrotron technology for measuring ovine meat quality. Meat Sci 2016; 117:122-9. [DOI: 10.1016/j.meatsci.2016.03.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2015] [Revised: 03/02/2016] [Accepted: 03/03/2016] [Indexed: 11/26/2022]
|
74
|
Bellerby T, Stevens D, Arnold T, Kerton L, Ortiz G, Price E, Collins D, Ahmed A, Carty S, Williamson L. AB1085-HPR Audit of Nurse-Led DGH Rheumatology Advice Line:. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
75
|
Berntzen B, Erwood L, Bellerby T, Price E, Collins D, Williamson L. THU0190 A Six-Week Progressive Resistance Training Class Improves Function and Fatigue in RA Patients:. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5554] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|